To be effective at treating, curing or preventing diseases, medicines must be available to the people and communities that need them. Through our Access to Medicines programs, Gilead is working to expand access to treatment wherever possible by helping people overcome barriers to get the medicines they need. Gilead is expanding disease awareness, addressing stigma and supporting front-line services and care in more than 140 low- and middle-income countries.
The United States healthcare landscape is complex and can be difficult for patients to navigate. To ease the burden this can place on patients and their families, our Patient Support Programs help provide patients with access to medicines, copay assistance and counseling across our therapeutic areas.
Patients received treatment at no cost using Gilead's Patient Assistance Program.
Of all individuals taking Gilead HIV medicines in the United States receive them through federal and state programs at substantially discounted prices.
Gilead Patient Support Programs
We offer support in navigating access and coverage for individuals who have insurance but are unsure whether their plan provides coverage or affordable copays for our medicines. Our case managers help individuals understand what their insurance will cover and provide research on potential alternative coverage and copay support.
Patient Assistance Programs
Individuals without insurance can apply to our Patient Assistance Program to receive treatment at no cost; those who qualify can receive their Gilead products free, directly from Gilead. In 2017, more than 40,000 individuals received treatment at no cost.
Assistance for Individuals Living with HIV
Approximately half of all individuals taking Gilead HIV medicines in the United States receive them through federal and state programs at substantially discounted prices. We have a long history of working with state AIDS Drug Assistance Programs (ADAP) to provide lower pricing for our HIV medicines.
The Gilead Truvada for PrEP Medication Assistance Program helps eligible HIV-negative adults in the United States who do not have insurance to obtain access to Truvada for PrEP. Gilead also offers a copay assistance program to help eligible patients with insurance offset out-of-pocket costs. Gilead recently enhanced these programs to ensure the assistance provided for Truvada is consistent, regardless of whether an individual needs access for prevention or treatment. The number of people prescribed Truvada for PrEP has increased to more than 153,000 in the United States.
Access to Our Medicines in Low- and Middle-Income Countries
In 2003, Gilead launched pioneering programs to provide access to our medicines in low- and middle-income countries. Since that time, we have learned that there is no one-size-fits-all solution to treatment access challenges. That’s why we work with public health officials, community advocates, researchers, doctors, and patients to understand barriers and opportunities, with a focus on communities impacted by HIV, viral hepatitis and visceral leishmaniasis.
To increase education and disease awareness, engage partners strategically and deliver medicines efficiently, we offer:
- Tiered pricing with discounts on medicines based on disease burden and national per-capita income.
- Responsible generic licensing of our products to enable high-quality, low-cost versions of our HIV and viral hepatitis medicines for individuals in low- and middle-income countries.
- Health systems strengthening to overcome access barriers by bolstering diagnostic, treatment and surveillance capacity.
- Collaborative research with international and local research leaders to target innovative therapies, inform drug delivery and help countries map their disease burdens.
- Partnerships with governments and non-governmental organizations to amplify our impact. We also work with in-country distributors that help register product and forecast drug demand.
- Advocacy for public health initiatives and policies that maximize patient reach and prevent new infections.
- Corporate giving to invest in programs that improve services for communities heavily affected by disease.
In 2018, more than 12 million people benefited from Gilead medicines in low- and middle-income countries.
Low- and middle-income countries supported by Gilead through our access to medicines programs.